Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroblastoma 3Pheochromocytoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Ganglioneuroblastoma 1Disease 1

Interventions

Magnetic Resonance Spectroscopy 3Prednisone 2Positron-Emission Tomography 2Lenalidomide 2Injections 2Dexamethasone 2Cyclophosphamide 2technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1obinutuzumab 1lortalamine 1fluciclovine F-18 1Vindesine 1Vincristine 1Transplantation, Autologous 1Thalidomide 1Rituximab 1Mitomycin 1Melphalan 1Doxorubicin 1Diagnosis 1Bleomycin 13-Iodobenzylguanidine 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Disease × 3-Iodobenzylguanidine × Clear all
NCT00126412 2019-05-31

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

GE Healthcare

Phase 3 Completed
251 enrolled
CNSEndocrine

Disease, Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡